Submit Manuscript  

Article Details


Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer

[ Vol. 21 , Issue. 11 ]

Author(s):

Drashti Desai and Pravin Shende*   Pages 1097 - 1102 ( 6 )

Abstract:


Immunotherapy emerges as a treatment strategy for breast cancer marker, diagnosis and treatment. In this review, monoclonal antibodies (mAbs)-based passive and peptide vaccines as active immunotherapy approaches like activation of B-cells and T-cells are studied. Passive immunotherapy is mAbs-based therapy effective against tumor cells, which acts by targeting HER2, IGF 1R, VEGF, BCSC and immune checkpoints. Neuropeptide Y (NPY) and GPCR are the areas of interest to target BC metastases for on-targeting therapeutic action. Neuropeptide S (NPS) or NPS receptor 1, acts as a biomarker for Neuroendocrine tumors (NET), mostly characterized by synaptophysin and chromogranin-A expression or Ki-67 proliferation index. The protein fusion technologies arise as a promising avenue in plant expression systems for increased recombinant Ab accumulation and cost-efficient purification. Recently, mAbs-based immunotherapy effectiveness is appreciated as a novel therapeutic combination of chemotherapy and immunotherapy to reduce the side effects and improve therapeutic responsiveness. Synthetic drug resistance will be overcome by mAbs-based therapy through several clinical trials and detection methods need to be optimized for accuracy and precision. Pharmacokinetic attributes need to be accessed for preferred receptor-agonist activity without ligand accumulation.

Keywords:

Antigen, receptor, immunity, immunotherapy, antibody, breast cancer.

Affiliation:

Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’S NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’S NMIMS, V. L. Mehta road, Vile Parle (W), Mumbai

Graphical Abstract:



Read Full-Text article